Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Systemic immune mediators predict therapeutic response and tumor-infiltrating lymphocyte intensity in triple-negative breast cancer

Ananda D. Lopes, Nayane A.L. Galdino, Amanda B. Figueiredo, Rafael C. Brianese, Katia L.P. Morais, Marina De Brot, Cynthia A.B.T, Osório, Andrea Teixeira-Carvalho, Vinicius F. Calsavara, Guilherme F.B. Evangelista, Natalia S. Alves, Fabiana B. Makdissi, Solange M. Sanches, Vladmir C. Cordeiro de Lima, Dirce M. Carraro, View ORCID ProfileKenneth J. Gollob
doi: https://doi.org/10.1101/2020.10.15.20212597
Ananda D. Lopes
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nayane A.L. Galdino
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda B. Figueiredo
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafael C. Brianese
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katia L.P. Morais
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marina De Brot
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia A.B.T
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Osório
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Teixeira-Carvalho
2Fundação Oswaldo Cruz (Fiocruz) - Instituto René Rachou, Belo Horizonte, MG, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vinicius F. Calsavara
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guilherme F.B. Evangelista
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalia S. Alves
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabiana B. Makdissi
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Solange M. Sanches
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladmir C. Cordeiro de Lima
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirce M. Carraro
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
3INCT- INCITO, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth J. Gollob
1A.C.Camargo Cancer Center, São Paulo, SP, Brazil
3INCT- INCITO, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kenneth J. Gollob
  • For correspondence: kenneth.gollob{at}accamargo.org.br
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer defined by the lack of expression of estrogen receptor, progesterone receptors, and of the human epithelial growth factor receptor 2. Neoadjuvant chemotherapy has proven efficacy in the treatment of TNBC, and a pathological complete response (pCR) is predictive of improved long-term survival. The immune response exerts a vital role in response to neoadjuvant chemotherapy, as indicated by the relation between the percentage of stromal tumor-infiltrating lymphocytes (TILs) in pre-treated tumor tissue samples and the likelihood of achieving pCR. Despite this, the relationship between the systemic immune response and the tumor microenvironment is unclear. In this prospective study, we determined the systemic plasma immune profile of TNBC patients before treatment using a panel of 27 immune mediators and measured the percentage of TILs from the same patients. Patients who demonstrated pCR had significantly higher systemic immune mediators; GM-CSF, FGF-basic, VEGF, IL-2, and IL-5, than the non-responders. Moreover, responders displayed a strong positive correlation between the cytokines IFN-γ and IL-7 with the percentage of TILs, while non-responders had a negative or no correlation. Finally, systemic immune mediator levels before treatment predict pCR (AUC range 0.64 - 0.71), and the combination of immune mediators and TILs improved pCR prediction (AUC 0.71 - 0.82). In conclusion, increased systemic immune mediators reflect increased TILs percentage and act as potential predictive biomarkers of pCR for TNBC patients submitted to neoadjuvant chemotherapy.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was funded with support from CNPq, PRONON, and INCT- INCITO/CNPq. KJG, DMC, ATC are CNPq research fellows. FAPESP, CAPES and CNPq for graduate student fellowships.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the local Ethics Committee. A written informed consent was obtained from each patient at the time of diagnosis and before the initiation of any procedure.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets generated during the current study are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 20, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Systemic immune mediators predict therapeutic response and tumor-infiltrating lymphocyte intensity in triple-negative breast cancer
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Systemic immune mediators predict therapeutic response and tumor-infiltrating lymphocyte intensity in triple-negative breast cancer
Ananda D. Lopes, Nayane A.L. Galdino, Amanda B. Figueiredo, Rafael C. Brianese, Katia L.P. Morais, Marina De Brot, Cynthia A.B.T, Osório, Andrea Teixeira-Carvalho, Vinicius F. Calsavara, Guilherme F.B. Evangelista, Natalia S. Alves, Fabiana B. Makdissi, Solange M. Sanches, Vladmir C. Cordeiro de Lima, Dirce M. Carraro, Kenneth J. Gollob
medRxiv 2020.10.15.20212597; doi: https://doi.org/10.1101/2020.10.15.20212597
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Systemic immune mediators predict therapeutic response and tumor-infiltrating lymphocyte intensity in triple-negative breast cancer
Ananda D. Lopes, Nayane A.L. Galdino, Amanda B. Figueiredo, Rafael C. Brianese, Katia L.P. Morais, Marina De Brot, Cynthia A.B.T, Osório, Andrea Teixeira-Carvalho, Vinicius F. Calsavara, Guilherme F.B. Evangelista, Natalia S. Alves, Fabiana B. Makdissi, Solange M. Sanches, Vladmir C. Cordeiro de Lima, Dirce M. Carraro, Kenneth J. Gollob
medRxiv 2020.10.15.20212597; doi: https://doi.org/10.1101/2020.10.15.20212597

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3281)
  • Dentistry and Oral Medicine (362)
  • Dermatology (274)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
  • Epidemiology (13340)
  • Forensic Medicine (19)
  • Gastroenterology (897)
  • Genetic and Genomic Medicine (5130)
  • Geriatric Medicine (479)
  • Health Economics (781)
  • Health Informatics (3253)
  • Health Policy (1138)
  • Health Systems and Quality Improvement (1189)
  • Hematology (427)
  • HIV/AIDS (1014)
  • Infectious Diseases (except HIV/AIDS) (14613)
  • Intensive Care and Critical Care Medicine (910)
  • Medical Education (475)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4901)
  • Nursing (261)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2516)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (346)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (540)
  • Pediatrics (1298)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (554)
  • Psychiatry and Clinical Psychology (4193)
  • Public and Global Health (7482)
  • Radiology and Imaging (1702)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (478)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (546)
  • Toxicology (71)
  • Transplantation (235)
  • Urology (203)